Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - adhoc news (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1312467
25 March 2022 03:52PM

CompuGroup Medical agrees to acquire INSIGHT Health


DGAP-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Takeover
CompuGroup Medical agrees to acquire INSIGHT Health

25-March-2022 / 15:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Koblenz, March 25, 2022 - Today, CompuGroup Medical Deutschland AG, a 100 % subsidiary of CompuGroup Medical SE & Co. KGaA (the "Company"), has entered into an agreement with RLPR AG and INSIGHT Health Holding GmbH to acquire all participation in the INSIGHT Health Group.

The INSIGHT Health Group, consisting of INSIGHT Health GmbH & Co. KG, its general partner INSIGHT Health Management GmbH and Gesellschaft für statistische Gesundheitsforschung mbH, all based in Waldems, Germany, is active in the field of so-called "market intelligence analysis" of health data. With the transaction, the Company is strengthening its offering in the area of market intelligence analysis of healthcare data. In the financial year 2021, the INSIGHT Health Group generated revenues of approximately EUR 36 million.

The purchase price for the 100% participation in the INSIGHT Health Group is between EUR 61 million and EUR 63 million, depending on future corporate developments. These amounts reflect the adjustments for net debt, working capital and trade tax on the capital gain payable by the target companies.

The closing of the transaction is subject to merger control clearance by the competent authorities. The closing is expected in the course of the coming months.


25-March-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)261 8000 7030
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1312467

 
End of Announcement DGAP News Service

1312467  25-March-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1312467&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.